TILT Biotherapeutics Secures $25.6M Series B Funding to Propel Next-Generation Oncolytic Immunotherapies

TILT Biotherapeutics Ltd is thrilled to announce its successful funding round, raising 25,600,000 to accelerate its pioneering efforts in oncology. As a clinical stage company dedicated to enhancing cancer therapies, TILT is forging new ground by harnessing the potential of oncolytic viruses to amplify T-cell therapies and immune checkpoint inhibitors. This significant investment will empower the company to further develop its innovative portfolio, including groundbreaking approaches to bolster tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T), and immune checkpoint inhibiting antibody treatments. The funds will be directed toward advancing the clinical development of TILT’s lead candidate, a TNFα/IL2 armed oncolytic adenovirus known as TILT-123 (Ad5/3-E2F-delta24-hTNFα-IRES-hIL2), which is currently being evaluated in multiple Phase I trials. Founded by Professor Akseli Hemminki, whose extensive research and hands-on clinical experience with almost 300 patients have laid a robust foundation for this venture, TILT Biotherapeutics Ltd continues to build on its legacy of innovation. Professor Hemminki’s journey—from groundbreaking lab discoveries to successful clinical applications—has inspired a collaborative environment where TILT works alongside some of the world’s leading research groups to synergize technologies for maximum therapeutic impact. With this new infusion of capital, TILT is poised to enhance its research capabilities and expand its clinical trial initiatives, ultimately aiming to transform the landscape of cancer treatment. This funding milestone not only signifies investor confidence in TILT’s vision but also brings renewed hope to patients awaiting more effective and less toxic cancer therapies. For additional information or inquiries, please contact BD (at) tiltbio.com.